Literature DB >> 15354384

Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures.

I Heider1, V Lehmensiek, Th Lenk, Th Müller, A Storch.   

Abstract

Levodopa and dopamine are metabolized to 3-O-methyldopa and 3-methoxytyramine, respectively, by the enzyme catechol-O-methyltransferase (COMT) leading to the production of the demethylated cofactor S-adenosylhomo-cysteine (SAH) and subsequently homocysteine (HC). Indeed, treatment of Parkinson's disease (PD) patients with levodopa leads to increased HC blood levels. Therefore, HC is discussed to be involved in the pathogenesis of PD as well as in enhanced progression of PD in patients treated with levodopa. Here we investigated the toxicity of HC and its derivatives SAH, homocysteic acid (HCA) and cysteic acid (CA) on tyrosine hydroxylase (TH)-positive neurons in primary mesencephalic cultures from rat in vitro. Furthermore, we evaluated the toxicity of HC on cultures stressed with the dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+). Incubation with HC or HCA did not result in significant effects on TH-positive neuron survival with concentrations up to 1 mM, but led to morphological changes of TH-positive cells with significantly fewer and shorter neurites at concentrations of > or = 100 microM after 48 h. In contrast, SAH and CA were toxic at concentrations of >100 microM after 48h. Furthermore, MPP+ showed strong toxicity towards TH-positive cells after 48 h (half-maximal toxic concentration: 20 microM), whereas co-incubation with HC for 24 or 48 h did not further alter TH-positive cell survival. Taken together, our results do not demonstrate relevant dopaminergic toxicity of HC in vitro, and therefore HC is most likely not involved in the pathogenesis of PD or in accelerating the progression of PD by levodopa.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354384     DOI: 10.1007/978-3-7091-0579-5_1

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  5 in total

1.  Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro.

Authors:  A G Ludolph; U Schaz; A Storch; S Liebau; J M Fegert; T M Boeckers
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

2.  Clinical experience with risperidone and memantine in the treatment of Huntington's disease.

Authors:  Eylem Sahin Cankurtaran; Elvan Ozalp; Haldun Soygur; Aysegul Cakir
Journal:  J Natl Med Assoc       Date:  2006-08       Impact factor: 1.798

Review 3.  Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID).

Authors:  Atticus H Hainsworth; Natalie E Yeo; Erica M Weekman; Donna M Wilcock
Journal:  Biochim Biophys Acta       Date:  2015-12-09

4.  Chronic exposure of homocysteine in mice contributes to dopamine loss by enhancing oxidative stress in nigrostriatum and produces behavioral phenotypes of Parkinson's disease.

Authors:  Nivedita Bhattacharjee; Rajib Paul; Anirudha Giri; Anupom Borah
Journal:  Biochem Biophys Rep       Date:  2016-02-26

5.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.